All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

REACH3 study: Should ruxolitinib become SoC for steroid-dependent or refractory chronic GvHD?

Jan 11, 2021
Share:

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Robert Zeiser, Medical Center – University of Freiburg, Freiburg, DE. We asked, Should ruxolitinib become standard of care for steroid-dependent or refractory chronic GvHD?

The standard first-line treatment for chronic GvHD includes systemic corticosteroids; however, patients who become steroid-dependent or refractory require additional treatments. Here, Zeiser reports the findings from the phase III REACH3 study on ruxolitinib versus best available therapy in patients with steroid-dependent or refractory chronic GvHD.

Read a summary of the phase III REACH3 study, here.

Share:

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox